RimonabantReport |
 |
Your INDEPENDENT source of news and reviews about the new diet drug rimonabant |
|||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
| About the Rimonabant Report & Medical Week News | |
The Rimonabant Report is produced by the staff of Medical Week, publisher of specialized online consumer health newsletters presenting the latest news and information on prevention, detection and treatment of major diseases.
Inquiries about our newsletters, including material to be considered for publication, should be directed to editor@medicalweek.org.
|
The chief executive of Medical Week News, Milton R. Benjamin, is a former editor of the Washington Post Company, and President of United Press International. He can be reached at
We subscribe to the HONcode principles of the HON Foundation. This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Aventis which markets it in Europe as Acomplia. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.
(c) 2004-2007 Medical Week News, Inc. All Rights Reserved
Last Updated: 03/05/2008
